Urbano Anido

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida et al. · Nature Medicine · 2019 · 571 citations · Full text

Medicine, Oncology, Urology +13

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment

Laura Muinelo‐Romay, María Vieito, Alicia Abalo et al. · Cancers · 2014 · 102 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non‐small‐cell lung cancer treated with pembrolizumab

Patricia Mondelo‐Macía, Jorge García, Luis León‐Mateos et al. · Molecular Oncology · 2021 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

Jesús García-Donás, Albert Font, Begoña Pérez‐Valderrama et al. · The Lancet Oncology · 2017 · 50 citations

Medicine, Oncology, Pharmacotherapy +13